Prestige Consumer Healthcare
PBH
Source: the SEC Form 13F filings of the managers we follow, latest for Q2 2026. How we use them
Value held
$233m
Combined value at quarter end
Last quarter
2 bought
0 sold or trimmed
Price at Q1 ’25 end
$85.97
+10.1% in the quarter
Share price change by quarter
-1.4%Q3 ’18
-18.5%Q4 ’18
-5.1%Q2 ’24
+4.7%Q3 ’24
+8.3%Q4 ’24
+10.1%Q1 ’25
Managers holding it, by quarter
1Q4 ’23
2Q1 ’24
2Q2 ’24
2Q3 ’24
2Q4 ’24
2Q1 ’25
1Q2 ’25
1Q3 ’25
1Q4 ’25
1Q1 ’26
2Q2 ’26
0Q3 ’26
Who holds it
| Ariel Investments | 2.3%$230m | Added +14% |
| Maverick Capital | 0.0%$2.4m | New |
About the company
- Sector
- Health care · Pharmaceutical Preparations
- Financial year ends
- 31 March
- Shares outstanding
- 47m at 31 Jul 2026
- SEC filings
- Annual reports and other filings on EDGAR
Revenue and profit
$597mMar ’14
$806mMar ’16
$1.0bnMar ’18
$963mMar ’20
$1.1bnMar ’22
$1.1bnMar ’24
$1.1bnMar ’26
| Year | Revenue | Net income |
|---|---|---|
| Year to Mar 2026 | $1.1bn | $190m |
| Year to Mar 2025 | $1.1bn | $215m |
| Year to Mar 2024 | $1.1bn | $209m |
| Year to Mar 2023 | $1.1bn | −$82.3m |
| Year to Mar 2022 | $1.1bn | $205m |
| Year to Mar 2021 | $943m | $165m |
| Year to Mar 2020 | $963m | $142m |
| Year to Mar 2019 | $976m | −$35.8m |
| Year to Mar 2018 | $1.0bn | $340m |
| Year to Mar 2017 | $882m | $69.4m |
| Year to Mar 2016 | $806m | $99.9m |
| Year to Mar 2015 | $715m | $78.3m |
| Year to Mar 2014 | $597m | $72.6m |